vwd group

04.07.2018 - 09:21

Mynewsdesk: Athera strengthens board with Johan Kördel

Athera strengthens board with Johan Kördel

Stockholm July 4, 2018 Johan Kördel has been elected as board director in Athera Biotechnologies AB, replacing Lennart Hansson who recently retired from Industrifonden. Professor Gunnar Olsson, former head of AstraZeneca CVD/GI Therapy area remains Charman of the Board. Otto Skolling and Svein Mathisen remain as board directors for Athera.

“We are very pleased to welcome Johan to the board, where he will further strengthen our focus on industrial business development and international venture financing” says Chairman Gunnar Olsson.

Dr Kördel trained as a Physical Chemist at University of Lund, Sweden, Scripps Research Institute, La Jolla, California and Harvard Medical School, Boston, Massachusetts. He is an associate professor in Physical Chemistry at the University of Lund, Sweden. He then joined the Pharmaceutical Industry and worked almost a decade in Pharmacia in Stockholm before he co-founded and worked as Senior Vice President of Research as well as Business Development of Biovitrum AB. Johan continued in Biotech as co-founder and CEO of Sound Biotech ApS and serving on numerous boards, both private and public. Since 2010, Johan has worked as a venture investor into Life Sciences at the Danish Lundbeckfonden. Today he is a board member of Acacia Pharma Ltd., Amplyx Pharmaceuticals Inc., Enterome S.A., Reneo Pharmaceuticals Inc., Saromics Biostructures AB and VHSquared Ltd..

For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se

Diese Pressemitteilung: http://www.mynewsdesk.com/se/ather-biotechnologies/pressreleases/athera-strengthens-board-with-johan-koerdel-2569731 wurde via Mynewsdesk versendet. Weitere Informationen finden Sie im Athera Biotechnologies AB: http://www.mynewsdesk.com/se/ather-biotechnologies

Shortlink zu dieser Pressemitteilung:
DB Connection Error...Please try again in a few minutes.

Permanentlink zu dieser Pressemitteilung:
Pressekontakt ===

Carina Schmidt

Athera Biotechnologies AB
Sankt Eriksgatan 117, 4th floor

EMail: c.schmidt@athera.se
Telefon: +46 (0)76-1938190

Athera Biotechnologies AB ===

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. Development of PC-mAb has been co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB. For more information: www.athera.se: http://www.athera.se/

: http://www.athera.se/

: http://www.athera.se/


Mehr Marktdaten und Kurse finden Sie auf www.finanztreff.de